Abstract
The contribution of drug metabolites to cyproheptadine (CPH)-induced alterations in endocrine pancreatic β-cells was investigated by examining the inhibitory activity of CPH and its biotransformation products, desmethylcyproheptadine (DMCPH), CPH-epoxide and DMCPH-epoxide, on hormone biosynthesis and secretion in pancreatic islets isolated from 50-day-old rats. Measurement of (pro)insulin (proinsulin and insulin) synthesis using incorporation of 3H-leucine showed that DMCPH-epoxide, DMCPH and CPH-epoxide were 22, 10 and 4 times, respectively, more potent than CPH in inhibiting hormone synthesis. The biosynthesis of (pro)insulin was also inhibited by CPH and DMCPH-epoxide in islets isolated from 21-day-old rat fetuses. The inhibitory action of CPH and its metabolites was apparently specific for (pro)insulin, and the synthesis of other islet proteins was not affected. Other experiments showed the metabolites of CPH were active in inhibiting glucose-stimulated insulin secretion but were less potent than the parent drug in producing this effect. CPH and its structurally related metabolites, therefore, have differential inhibitory activities on insulin synthesis and release. The observation that CPH metabolites have higher potency than CPH to inhibit (pro)insulin synthesis, when considered with published reports on the disposition of the drug in rats, indicate that CPH metabolites, particularly DMCPH-epoxide, are primarily responsible for the insulin depletion observed when the parent compound is given to fetal and adult animals.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- CPH:
-
cyproheptadine
- CPH-epoxide:
-
cyproheptadine-10-11-epoxide
- DMCPH:
-
desmethylcyproheptadine
- DMCPH-epoxide:
-
desmethylcyproheptadine-10,11-epoxide
- HPLC:
-
high-performance liquid chromatography
- KBB:
-
Krebs biocarbonate buffer
References
ASPLUND, K. and HELLERSTROM, C. (1972). Glucose metabolism of pancreatic islets isolated from neonatal rats. Horm. Metab. Res. 4:159–163.
CAMPBELL, I.L., HELLQUIST, L.N.B. and TAYLOR, K.W. (1982). Insulin biosynthesis and its regulation. Clin. Sci. 62:449–455.
CHANG, A.Y. and DIANI, A.R. (1984). Chemically and hormonally induced diabetes mellitus. In: The Diabetic Pancreas. (B.W. Volk and K.F. Wellman, eds.), pp. 415–438. Plenum Press, New York.
CHOW, S.A. and FISCHER, L.J. (1986). Susceptibility of fetal rat endocrine pancreas to the diabetogenic action of cyproheptadine. Toxicol. Appl. Pharmacol. 84:264–277.
CHOW, S.A. and FISCHER, L.J. (1987). Metabolism and distribution of cyproheptadine and desmethylcyproheptadine in pregnant and fetal rats. Drug Metab. Dispos. 15:740–748.
CHOW, S.A., RICKERT, D.E. and FISCHER, L.J. (1988). Evidence that drug metabolites are involved in cyproheptadine-induced loss of pancreatic insulin. J. Pharmacol. Exp. Ther. 246:143–149.
DONATSCH, P., LOWE, D.A., RICHARDSON, B.P. and TAYLOR, P. (1980). Mechanism by which cyproheptadine inhibits insulin secretion. Br. J. Pharmacol. 70:355–362.
DUDEK, R.W., HELLERSTROM, C., LEWIS, N.J., JOHNSON, R.C. and FREINKEL, N. (1980). Morphologic study of cultured pancreatic fetal islets during maturation of the insulin stimulus-secretion mechanism. Diabetes 29:15–21.
EAGLE, H., (1955). Nutrition needs of mammalian cells in tissue culture. Science 122:501–504.
ENGELHARDT, E.L., ZELL, H.C., SAARI, W.S., CHRISTY, M.E., COLTON, C.D., STONE, C.A., STAVORSKI, J.M., WENGER, H.C. and LUDDEN, C.T. (1965). Structure-activity relationships in the cyproheptadine series. J. Med. Chem. 8:829–835.
FINNEY, D.J. (1952). Statistical Methods in Biological Assay. Charles Griffin and Company, Ltd., London.
FISCHER, L.J. and RICKERT, D.E. (1975). Pancreatic islet-cell toxicity. CRC Crit. Rev. Toxicol. 3:231–263.
FISCHER, L.J., THIES, R.L. and CHARKOWSKI, D. (1978). High performance liquid chromatographic separation of insulin, glucagon and somatostatin. Anal. Chem. 50:2143–2144.
FISCHER, L.J., WOLD, J.S. and RICKERT, D.E. (1973). Structure-activity relationships in drug-induced pancreatic islet cell toxicity. Toxicol. Appl. Pharmacol. 26:288–298.
FUJII, S. (1979). Development of pancreatic endocrine cells in the rat fetus. Arch. Histol. Jap. 42:467–479.
GOLD, G., POU, J., NOWLAIN, R.M. and GRODSKY, G.M. (1984). Effects of monensin on conversion of proinsulin to insulin and secretion of newly synthesized insulin in isolated rat islets. Diabetes 33:1019–1024.
GOLDSTEIN, A. (1964). Biostatistics: An Introductory Text. MacMillan Publishing Co., New York.
GRILL, V., LAKE, W. and FREINKEL, N. (1981). Generalized dimunition in response to nutrients as insulin-releasing agents during the early neonatal period in the rat. Diabetes 30:56–63.
HINTZE, K.L., GROW, A.B. and FISCHER, L.J. (1977). Cyproheptadine-induced alterations in rat insulin synthesis. Biochem. Pharmacol. 26:2021–2027.
HINTZE, K.L., WOLD, J.S. and FISCHER, L.J. (1975). Disposition of cyproheptadine in rats, mice and human and identification of a stable epoxide metabolite. Drug Metab. Dispos. 3:1–9.
KERVRAN, A. and RANDON, J. (1980). Development of insulin release by fetal rat pancreas in vitro: Effects of glucose, amino acids and theophylline. Diabetes 29:673–678.
LACY, P.E. and KOSTIANOVSKY, M. (1967). Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16:35–39.
LOUBATIERES, A. (1972). Therapeutic modification of islet function. In: Handbook of Physiology, Vol. 1, The Endocrine Pancreas (N. Freinkel and D. Steiner, eds.), pp. 653–664. The American Physiological Society, Baltimore.
McEVOY, R.C. (1981). Changes in the volumes of A-, B- and D-cell populations in the pancreatic islets during postnatal development of the rat. Diabetes 30:813–817.
MANS, R.J. and NOVELLI, G.D. (1961). Measurement of the incorporation of radioactive amino acids into proteins by a filter disk method. Arch. Biochem. Biophys. 94:48–53.
OTT, L. (1977). An Introduction to Statistical Methods and Data Analysis. Duxbury Press, North Scituate, MA.
RICHARDSON, B.P., McDANIEL, M.L. and LACY, P.E. (1975). Effects of cyproheptadine on insulin secretion by isolated perfused rat islets. Diabetes 24:836–841.
RICKERT, D.E. and FISCHER, L.J. (1975). Cyproheptadine and beta cell function in the rat: Insulin secretion from pancreas. Proc. Soc. Exp. Biol. Med. 150:1–6.
STARR, J.I., HORWITZ, D.L., RUBENSTEIN, A.H. and MAKO, M.E.. (1979). Insulin, proinsulin and C-peptide. In: Methods of Hormone Radioimmunoassay. (B.M. Jaffe and H.R. Behrman, eds.), 2nd Ed., pp. 613–642. Academic Press, New York.
WOLD, J.S. and FISCHER, L.J. (1972). The tissue distribution of cyproheptadine and its metabolite in rats and mice. J. Pharmacol. Exp. Ther. 183:188–196.
WOLD, J.S., LONGNECKER, D.S. and FISCHER, L.J. (1971). Species dependent pancreatic islet toxicity produced by cyproheptadine: Alterations in beta cell structure and function. Toxicol. Appl. Pharmacol. 19:188–201.
Author information
Authors and Affiliations
Additional information
Recipient of a Society of Toxicology Predoctoral Research Fellowship.
Present address: Department of Biochemistry, The University of Hong Kong, Hong Kong.
Rights and permissions
About this article
Cite this article
Chow, S.A., Falany, J.L. & Fischer, L.J. Cyproheptadine metabolites inhibit proinsulin and insulin biosynthesis and insulin release in isolated rat pancreatic islets. Cell Biol Toxicol 5, 129–143 (1989). https://doi.org/10.1007/BF00122648
Issue Date:
DOI: https://doi.org/10.1007/BF00122648